Relative antigenicity in mice of H1N1, H3N2 and B strains present in inactivated influenza virus vaccines
- PMID: 3582601
- DOI: 10.1007/BF00145074
Relative antigenicity in mice of H1N1, H3N2 and B strains present in inactivated influenza virus vaccines
Abstract
The results of a study on serum HAI and neutralizing antibodies induced in mice by whole influenza virus vaccines containing A/Brazil/11/78 (H1N1), A/Bangkok/1/79 (H3N2) and B/Singapore/222/79 viruses are reported. According to the GMT of HAI, the antigenic potency of the three vaccine strains appear to be different. The A/Brazil/11/78 antigen induced the lowest HAI antibody responses and the A/Bangkok/1/79 antigen the greatest. This behaviour, with a few exceptions, was noted regardless of the HA amount (0.08 microgram 0.4 microgram, 2 micrograms) of each strain present in the vaccine, the number of doses (one or two), or the kind of preparation (monovalent or trivalent). The data obtained with the neutralization test with vaccines with medium HA content are concordant with previous findings. On the basis of the ratios of the GMT of the neutralizing antibodies to the GMT of the HAI antibodies, it was concluded that the HAI antibodies to A/Bangkok/1/79 antigen possess, on the whole, a neutralizing activity that is higher than that found for the HAI antibodies to A/Brazil/11/78 and B/Singapore/222/79 strains. For the latter strains, the neutralizing activity increased after the second dose. The observation of the different degrees of antigenicity of the three vaccine strains suggests that, with currently used inactivated influenza virus vaccines containing equivalent amounts of all three antigens, the dosage should be taken into consideration when the vaccines are used for subjects lacking in previous exposure to vaccine strains.
Similar articles
-
Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.Pediatrics. 2006 Sep;118(3):e579-85. doi: 10.1542/peds.2006-0201. Pediatrics. 2006. PMID: 16950949 Clinical Trial.
-
Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.J Virol. 2017 Nov 30;91(24):e01581-17. doi: 10.1128/JVI.01581-17. Print 2017 Dec 15. J Virol. 2017. PMID: 28978710 Free PMC article.
-
Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.Vaccine. 2017 Sep 25;35(40):5366-5372. doi: 10.1016/j.vaccine.2017.08.021. Epub 2017 Aug 22. Vaccine. 2017. PMID: 28844407
-
Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.Vaccine. 2014 Jan 23;32(5):535-43. doi: 10.1016/j.vaccine.2013.12.002. Epub 2013 Dec 14. Vaccine. 2014. PMID: 24342248
-
Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.Vaccine. 2013 May 1;31(19):2358-65. doi: 10.1016/j.vaccine.2013.03.008. Epub 2013 Mar 13. Vaccine. 2013. PMID: 23499604 Clinical Trial.
Cited by
-
Simultaneous influenza and pneumococcal vaccination in elderly individuals.Eur J Epidemiol. 1997 Apr;13(3):287-91. doi: 10.1023/a:1007398606807. Eur J Epidemiol. 1997. PMID: 9258527 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical